# Meeting of the Advisory Committee on Immunization Practices (ACIP)

**Center for Disease Control and Prevention**

**1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Atlanta, Georgia**

**October 24-25, 2007**

### Agenda Item

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Purpose</th>
<th>Presider/Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday October 24</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 8:00  | **Welcome & Introductions**                     |         | Dr. Julie Gerberding (Director, CDC)  
Dr. Dale Morse (Chair, ACIP)  
Dr. Larry Pickering (Executive Secretary, ACIP; CDC) |
| 8:30  | **Influenza Vaccines**                          |         | Dr. Anthony Fiore (CDC/NCIRD/ID)  
Dr. Greg Wallace, CDC/NCIRD/ISD) |
|       | • Overview of session and influenza vaccine update | Information  
Discussion  
Vote  
VFC Vote |
|       | • Use of live attenuated influenza vaccine (LAIV) in 24-59 month old children |         | Dr. Anthony Fiore (CDC/NCIRD/ID)  
Dr. Kathleen Neuzil (ACIP, WG Chair)  
Dr. Anthony Fiore (CDC/NCIRD/ID) |
|       | • Summary of CDC-CSTE consultants meeting: Influenza vaccine recommendations for 5-18 year olds | Information  
Discussion |
|       | • Summary of ACIP Influenza Working Group discussions |         | Dr. Lisa Prosser (Harvard Medical School)  
Dr. Benjamin Schwartz (CDC/NVPO) |
|       | Cost-effectiveness of Influenza Vaccination: Updated Estimates for Children Aged 2-4 Years | Information  
Discussion |
|       | • Federal Interagency Working Group: Draft Guidance on Pandemic Vaccine Prioritization |         | |
| 11:00 | **Break**                                       |         |                      |
| 11:30 | **Pediatric Use of Pneumococcal Vaccines**      |         | Dr. Julie Morita (ACIP, WG Chair)  
Dr. Pekka Nuorti (CDC/NCIRD/DBD) |
|       | • Use of pneumococcal conjugate vaccine (PCV7) in 24-59 month old children who are incompletely vaccinated | Information  
Discussion  
Vote |
| 12:30 | **Lunch**                                       |         |                      |
| 1:30  | **Meningococcal Conjugate Vaccine (MCV4)**       |         | Dr. Carol Baker (ACIP, WG Chair)  
Dr. Thomas Clark (CDC/NCIRD/DBD)  
Dr. Greg Gilmet (sanofi pasteur) |
|       | • Introduction                                   | Introduction  
Information  
Information |
|       | • Update: meningococcal vaccine safety           |         | Dr. Amanda Cohn (CDC/NCIRD/DBD)  
Dr. Greg Wallace (CDC/NCIRD/ISD)  
Dr. Amanda Cohn (CDC/NCIRD/DBD) |
|       | • Immunogenicity and safety of Menactra® (MCV4) in 2-10 year old children | Information  
Discussion  
Vote  
VFC Vote |
|       | • Proposed recommendations for use of MCV4 in 2-10 year old children at increased risk of meningococcal disease |         |                      |
|       | • Considerations for routine use of MCV4 in 2-10 year old children | Information  
Discussion  
Vote  
VFC Vote |
| 3:15  | **Childhood and Adolescent Immunization Schedule** | Information  
Discussion  
Vote |
| 3:45  | **Break**                                       |         |                      |
| 4:00  | **Combination Vaccines**                        |         | Ms. Patsy Stinchfield (ACIP, WG Chair)  
Dr. Greg Wallace (CDC/NCIRD/ISD)  
Dr. Wayde M. Weston (GSK) |
|       | • Update: Combination Vaccines Working Group     | Information  
Information  
Information |
|       | • Impact of combination vaccines                 |         |                      |
|       | • Immunogenicity and safety of Kinrix™ (combination DTaP-IPV vaccine) in children 4-6 years of age | Information  
Information  
Information |
Thursday October 25

8:00 **Unfinished Business**

8:30 **Human Papillomavirus (HPV) Vaccines**

- Introduction
- Overview of HPV vaccine trial data
- Quadrivalent HPV vaccine cross-protection
- Bivalent HPV baccine ASO4 adjuvant system
- Bivalent HPV vaccine clinical overview and safety review
- Outcomes related to HPV 6/11: recurrent respiratory papillomatosis and genital warts
- Issues for ACIP consideration

10:45 **Break**

11:00 **Immunization Safety**

- Introduction
- Early Thimerosal Exposure and Neuropsychological Outcomes at 7-10 Years
- Summary of syncope reports to the Vaccine Adverse Events Reporting System (VAERS), Jan 2005-July 2007
- Update: varicella vaccine safety 1995-2005

12:00 **Lunch**

1:00 **Rotavirus Vaccines**

- Working Group update
- GSK’s Human Rotavirus Vaccine Rotarix®
- PRV (RotaTeq®) update
  - Coverage, adherence with age recommendations
  - Safety monitoring update

2:30 **Update: Hepatitis B**

- Hepatitis B vaccination of adults
- Identification and public health management of persons chronically infected with hepatitis B virus

3:00 **Agency Updates** (CDC/CCID/NCIRD, CMS, DOD, DVA, FDA, HRSA, IHS, NIH, NVPO)

3:15 Public Comment

3:30 Adjourn
### Acronyms

<table>
<thead>
<tr>
<th>ACIP</th>
<th>Advisory Committee on Immunization Practices</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCID</td>
<td>Coordinating Center for Infectious Diseases</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control &amp; Prevention</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>DBD</td>
<td>Division of Bacterial Diseases [of NCIRD]</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DSTDP</td>
<td>Division of Sexually Transmitted Diseases Prevention [of NCHHSTP]</td>
</tr>
<tr>
<td>DVA</td>
<td>Department of Veterans Affairs</td>
</tr>
<tr>
<td>DVD</td>
<td>Division of Viral Diseases [of NCIRD]</td>
</tr>
<tr>
<td>DVH</td>
<td>Division of Viral Hepatitis [of NCHHSTP]</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>ID</td>
<td>Influenza Division [of NCIRD]</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>ISD</td>
<td>Immunization Services Division [of NCIRD]</td>
</tr>
<tr>
<td>ISO</td>
<td>Immunization Safety Office (of CDC/OD/Office of the Chief Science Officer)</td>
</tr>
<tr>
<td>NCHHSTP</td>
<td>National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/CCID]</td>
</tr>
<tr>
<td>NCIRD</td>
<td>CDC National Center for Immunization &amp; Respiratory Diseases [of CDC/CCID]</td>
</tr>
<tr>
<td>NCPDCID</td>
<td>National Center for Preparedness, Detection, and Control of Infectious Diseases</td>
</tr>
<tr>
<td>NCZVED</td>
<td>National Center for Zoonotic, Vector-Borne, and Enteric Diseases [of CDC/CCID]</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NVAC</td>
<td>National Vaccine Advisory Committee</td>
</tr>
<tr>
<td>NVPO</td>
<td>National Vaccine Program Office</td>
</tr>
<tr>
<td>OCSO</td>
<td>Office of the Chief Science Officer [of OD]</td>
</tr>
<tr>
<td>OD</td>
<td>Office of the Director [of CDC]</td>
</tr>
<tr>
<td>TBD</td>
<td>to be determined</td>
</tr>
<tr>
<td>WG</td>
<td>Work Group</td>
</tr>
</tbody>
</table>
This document can be found on the CDC website at: